Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CAP256V2LS in Healthy Adults
NCT04408963Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAP256V2LS in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 4 more. Started Mar 2022; status: completed.
02
Drugs
CAP256V2LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04408963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408963.